SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023)
- PMID: 38822976
- PMCID: PMC11466990
- DOI: 10.1007/s12094-024-03502-8
SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023)
Abstract
Cancer-related anorexia-cachexia syndrome (CACS) is a debilitating condition afflicting up to 80% of advanced-stage cancer patients. Characterized by progressive weight loss, muscle wasting, and metabolic abnormalities, CACS significantly compromises patients' quality of life and treatment outcomes. This comprehensive review navigates through its intricate physiopathology, elucidating its stages and diagnostic methodologies. CACS manifests in three distinct stages: pre-cachexia, established cachexia, and refractory cachexia. Early detection is pivotal for effective intervention and is facilitated by screening tools, complemented by nutritional assessments and professional evaluations. The diagnostic process unravels the complex interplay of metabolic dysregulation and tumor-induced factors contributing to CACS. Management strategies, tailored to individual patient profiles, encompass a spectrum of nutritional interventions. These include dietary counseling, oral nutritional supplements, and, when necessary, enteral nutrition and a judicious use of parenteral nutrition. Specific recommendations for caloric intake, protein requirements, and essential nutrients address the unique challenges posed by CACS. While pharmacological agents like megestrol acetate may be considered, their use requires careful evaluation of potential risks. At its core, this review underscores the imperative for a holistic and personalized approach to managing CACS, integrating nutritional interventions and pharmacological strategies based on a nuanced understanding of patient's condition.
Keywords: Anorexia; Anorexia-cachexia syndrome; Cachexia; Cancer; Malnutrition; Sarcopenia.
© 2024. The Author(s).
Conflict of interest statement
ASR has participated in conferences for MSD, BMS, Novartis, Pierre Fabre, Regeneron, Merck Serono, Immunocore, Sanofi Aventis and Viatris; has participated in advisories for MSD, MS, Novartis, Immunocore, Regeneron; and he is on the steering committee of an IO biotech trial. LCG reports advisory board, speaker, personal fees from Roche; speaker, personal fees from Astra Zeneca, BMS, Merck Serono and MSD; advisory board from Eisai and speaker from Kyowa Kirin, Grunenthal and Pfizer. MMC, ABC, CBZ, YEA, MMT, KMM, MMS, MZP have nothing to disclose.
Figures
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
